Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models

Regulation of FANCD2 by the mTOR Pathway Contributes to the Resistance of Cancer Cells to DNA Double-Strand Breaks

(2013) C. Shen et al.   CANCER RESEARCH

A Survivin-Associated Adaptive Response in Radiation Therapy

(2013) D. J. Grdina et al.   CANCER RESEARCH

PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer

(2013) Giovanni Luca Gravina et al.   ENDOCRINE-RELATED CANCER

Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients

(2013) Lovisa Farnebo et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma

(2012) Ravi S. Narayan et al.   CURRENT PHARMACEUTICAL DESIGN

Autophagy and ionizing radiation in tumors: The “survive or not survive” dilemma

(2012) Silvia Palumbo et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Silencing of MicroRNA-21 Confers Radio-Sensitivity through Inhibition of the PI3K/AKT Pathway and Enhancing Autophagy in Malignant Glioma Cell Lines

(2012) Ho-Shin Gwak et al.   PLoS One

Tumourigenicity and radiation resistance of mesenchymal stem cells

(2011) Filippo P. D'Andrea et al.   ACTA ONCOLOGICA

Regulation of protein stability by GSK3 mediated phosphorylation

(2011) Chong Xu et al.   CELL CYCLE

The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells

(2011) G. L. Gravina et al.   ENDOCRINE-RELATED CANCER

NF- B Is Required for Smac Mimetic-Mediated Sensitization of Glioblastoma Cells for  -Irradiation-Induced Apoptosis

(2011) R. Berger et al.   MOLECULAR CANCER THERAPEUTICS

MEK/ERK Inhibitor U0126 Increases the Radiosensitivity of Rhabdomyosarcoma Cells In vitro and In vivo by Downregulating Growth and DNA Repair Signals

(2011) F. Marampon et al.   MOLECULAR CANCER THERAPEUTICS

Glycogen synthase kinase 3β inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neurons

(2011) Eddy S. Yang et al.   NEURO-ONCOLOGY

c-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3β activity

(2010) C Quintavalle et al.   CELL DEATH AND DIFFERENTIATION

Glycogen Synthase Kinase-3 Plays a Central Role in Mediating Glucocorticoid-Induced Apoptosis

(2010) Rachel Spokoini et al.   MOLECULAR ENDOCRINOLOGY

Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis

(2010) K-S Chan et al.   Cell Death & Disease

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

(2009) R Diaz et al.   BRITISH JOURNAL OF CANCER

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Glycogen synthase kinase 3β induces apoptosis in cancer cells through increase of survivin nuclear localization

(2008) Jiansha Li et al.   CANCER LETTERS

Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability

(2008) Q. Xue et al.   CANCER RESEARCH

Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair

(2008) M. Toulany et al.   MOLECULAR CANCER THERAPEUTICS

Cyclin D1 in low-dose radiation-induced adaptive resistance

(2008) K M Ahmed et al.   ONCOGENE

Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors

(2008) Claudio Festuccia et al.   PROSTATE